Altimmune (ALT) Long-Term Debt Repayments (2013 - 2019)
Altimmune (ALT) reported Long-Term Debt Repayments of $105062.0 for Q4 2019, up 241.17% quarter-over-quarter from $30795.0 in Q3 2019.
Altimmune (ALT) Long-Term Debt Repayments (2013 - 2019) Analysis & Trends
Altimmune (ALT) has 6 years of Long-Term Debt Repayments data on file, last reported at $105062.0 in Q4 2019.
- Long-Term Debt Repayments for Q4 2019 came in at $105062.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2020 was $135857.0 (changed 0.0% YoY), and the FY2020 annual result was $632000.0, up 116.44% from the prior year.
- Long-Term Debt Repayments grew to $105062.0 in Q4 2019 per ALT's latest filing, from $30795.0 in the prior quarter.
- Over five years, Long-Term Debt Repayments peaked at $105062.0 in Q4 2019 and troughed at -$250009.0 in Q3 2015.
- A 4-year average of -$64639.6 and a median of $8017.0 in 2016 frame the typical range for Long-Term Debt Repayments.
- The sharpest annual moves came in 2015 and 2017: Long-Term Debt Repayments slipped 0.0% in 2015, then jumped 15995.96% in 2017.
- A 4-year view of Long-Term Debt Repayments shows it stood at -$250009.0 in 2015, then surged by 132.4% to $80999.0 in 2016, then tumbled by 80.33% to $15935.0 in 2017, then soared by 559.32% to $105062.0 in 2019.
- Business Quant data shows ALT's Long-Term Debt Repayments at $105062.0 in Q4 2019, $30795.0 in Q3 2019, and $15935.0 in Q2 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Repayments (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -21,671.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Altimmune | 336.67 Mn | 336.67 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | 105,062.00 |
| Dec 31, 2019 | 105,062.00 |
| Sep 30, 2019 | 30,795.00 |
| Sep 30, 2019 | 30,795.00 |
| Jun 30, 2017 | 15,935.00 |
| Jun 30, 2017 | 15,935.00 |
| Dec 31, 2016 | 80,999.00 |
| Dec 31, 2016 | 80,999.00 |
| Jun 30, 2016 | 99.00 |
| Jun 30, 2016 | 99.00 |
| Sep 30, 2015 | -250,009.00 |
| Sep 30, 2015 | -250,009.00 |
| Jun 30, 2015 | -249,999.00 |
| Jun 30, 2015 | -249,999.00 |
| Mar 31, 2015 | -249,999.00 |
| Mar 31, 2015 | -249,999.00 |
| Dec 31, 2014 | -249,999.00 |
| Dec 31, 2014 | -249,999.00 |
| Sep 30, 2014 | -249,999.00 |
| Sep 30, 2014 | -249,999.00 |